Hfplus 100 Tablet is a combination medication containing Sacubitril 49 mg and Valsartan 51 mg, indicated for the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril is a neprilysin inhibitor that enhances the levels of natriuretic peptides, promoting vasodilation, natriuresis, and diuresis, thereby reducing cardiac workload. Valsartan is an angiotensin II receptor blocker (ARB) that inhibits the effects of angiotensin II, leading to vasodilation and decreased aldosterone secretion, which further contributes to blood pressure reduction and decreased cardiac remodeling. The synergistic action of these two agents improves cardiac function, reduces hospitalization rates, and lowers mortality in patients with chronic heart failure. Hfplus 100 is administered orally and should be prescribed under medical supervision, with dosage adjustments based on renal function, blood pressure, and tolerability. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy, severe hepatic impairment, or pregnancy. Common adverse effects may include hypotension, hyperkalemia, dizziness, and renal impairment. Regular monitoring of renal function, electrolytes, and blood pressure is recommended during therapy to ensure safety and efficacy. Hfplus 100 Tablet represents an important therapeutic option for optimizing heart failure management.